Oil

Japan core CPI moderates in February

Pharma Q4 mixed: revenues missed by 7.7%, stocks down 7.2%. CORT misses estimates, LLY beats but drops 9.2%. RPRX up 2.9% despite miss.

XOM hits all-time high, up 34% YTD. Valuation at 21x forward P/E, but analysts see ~8% downside risk.

Kalshi eyes $22B valuation, up from $11B, as rivals Polymarket seek $20B. New VC fund 5(c) Capital raises $35M.

Deutsche Bank now expects the ECB to hike rates to 2.5% in 2026, citing energy-driven inflation above 3%. Two hikes are seen in June and September, though the outlook remains highly dependent on oil prices and geopolitical developments.

CCL down 13.6% despite revenue beat; VIK up 27.8% revenue, down 7.3% stock. HGV misses estimates, down 17.2%.

BNZ’s Breman flags near-term inflation rise, warns on second-round risks Neutral-to-hawkish.